Eric Lefkofsky Looks Forward To Utilizing Big Data Analytics to Revolutionize Cancer Medicine through Tempus
Cancer is among the diseases that have proven to be dynamic. Medical practitioners are also unable to gain a better understanding of the disease, and these are among the main reasons why they are unable to formulate suitable forms of therapy. Individuals such as Eric Lefkofsky are striving to ensure that they can revolutionize the types of medication being used by people who have been affected by cancer. As an executive at Tempus, Lefkofsky has now focused on utilizing big data analytics.
It is evident that when treating cancer, you must learn more about the type of cancer affecting the patient. The research presented by most scientists also showcases that cancer is a genetic disease. As a result, personalized treatment options are suitable since the medical practitioners can focus on learning about the patient’s genetic makeup in a bid to come up with a form of therapy that will eliminate cancer within their body. The data from such forms of treatment would come in handy if it were to be stored in one place together with the data from other patients who have undergone the same procedures.
Although electronic records have come in handy over the years, there is still a long way to go. It is also good to note that there is a huge difference between information about effective forms of treatment and the collection of patient data. The main challenge is that not all patient data is accessible. When launching Tempus, Lefkofsky aimed at ensuring that he would bring the molecular data and clinical records closer as a way of ensuring that patients could easily get access to personalized forms of treatment depending on the patient data that is present.
Eric Lefkofsky has also ensured that the cancer patient data can be gathered in different ways, including big data analytics. The data in this context is mainly gathered by learning more about the prescriptions that some of these patients have been using. Insurance companies should also be providing the necessary information to researchers and other medical practitioners. Lefkofsky has also made sure that Tempus could make use of artificial intelligence. The firm has also been making sure that physicians have access to the tools that they need at their disposal. Read more about Eric Lefkofsky: https://www.americaninno.com/chicago/funding-chicago/cancer-fighting-startup-tempus-raises-80m-in-new-funding/